Net income surged to $14.2M from $0.7M YoY, showing a massive turnaround in profitability.
Operating income grew from $1.6M to $22.3M due to strong operating leverage.
Executed $49.1M in share repurchases during the quarter.
Confirmed ongoing material weaknesses in internal controls over financial reporting.
The Q1 2026 filing presents a company in a high-stakes transition. On one hand, the operational metrics are compelling: revenue is accelerating, patient volume is growing, and the company has finally achieved meaningful GAAP profitability. The shift toward a positive operating cash flow of $33.1 million suggests that the business model can indeed scale without constant external capital infusions. However, the synthesis of the data reveals a tension between operational success and financial risk. The aggressive use of cash for buybacks while maintaining $262.5 million in long-term debt and struggling with internal control deficiencies suggests a management team eager to signal value to the market, perhaps prematurely. Investors are left to weigh the genuine growth in patient visits and clinician headcount against the fragility of a revenue base heavily dependent on a few large payors and a balance sheet burdened by significant intangible assets.